Studies comparing immunogenicity of biosimilars and their reference products for the treatment of plaque psoriasis.

Studies comparing immunogenicity of biosimilars and their reference products that are used for the treatment of plaque psoriasis. (*) indicates when a study reported EU-reference product. ADA percentages indicate the number of patients who developed anti-drug antibodies. NAb percentages indicate the percentage of total patients who developed neutralizing antibodies.